Cargando…
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide
Glioblastoma (GBM) is a malignant, primary brain tumor, highly resistant to conventional therapies. Temozolomide (TMZ) is a first line therapeutic agent in GBM patients, however, survival of such patients is poor. High level of DNA repair protein, O(6)-methylguanine-DNA-methyltransferase (MGMT) and...
Autores principales: | Ciechomska, Iwona Anna, Marciniak, Marta Patrycja, Jackl, Judyta, Kaminska, Bozena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224489/ https://www.ncbi.nlm.nih.gov/pubmed/30450051 http://dx.doi.org/10.3389/fphar.2018.01271 |
Ejemplares similares
-
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells
por: Ciechomska, Iwona Anna, et al.
Publicado: (2016) -
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis
por: Oh, Su Young, et al.
Publicado: (2015) -
Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294
por: PANG, ALAN LAP-YIN, et al.
Publicado: (2014) -
Examining the effects of the histone methyltransferase inhibitor BIX-01294 on histone modifications and gene expression in both a clinical population and mouse models
por: Chase, Kayla A., et al.
Publicado: (2019) -
Mechanism of G9a inhibitor BIX-01294 acting on U251 glioma cells
por: Guo, Ai-Shun, et al.
Publicado: (2016)